

Copy for the Elected Office (EO/US)  
PATENT COOPERATION TREATY

PCT/EP00/07291

10/048196

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING  
OF A CHANGE

(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

RECEIVED

PRIVETT, Kathryn, Louise  
SmithKline Beecham  
Corporate Intellectual Property  
(CN9.25.1)  
980 Great West Road  
Brentford, Middlesex TW8 9GS  
ROYAUME-UNI

JUN 03 2002

TECH CENTER 1600/2900

Date of mailing (day/month/year) 21 February 2002 (21.02.02)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference FB/BM45402	
International application No. PCT/EP00/07291	International filing date (day/month/year) 27 July 2000 (27.07.00)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address PRIVETT, Kathryn, Louise SmithKline Beecham Two New Horizons Court Brentford Middlesex TW8 9EP United Kingdom	State of Nationality	State of Residence
	Telephone No. +44 181 975 2585	
	Facsimile No. +44 181 975 6294	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address PRIVETT, Kathryn, Louise SmithKline Beecham Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom	State of Nationality	State of Residence
	Telephone No. +44 20 8047 5000	
	Facsimile No. +44 20 8047 6894	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned  
☐ the International Searching Authority ☒ the elected Offices concerned  
☐ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Dominique DELMAS Telephone No.: (41-22) 338.83.38
---	--

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 23 March 2001 (23.03.01)	
<b>International application No.</b> PCT/EP00/07291	<b>Applicant's or agent's file reference</b> FB/BM45402
<b>International filing date</b> (day/month/year) 27 July 2000 (27.07.00)	<b>Priority date</b> (day/month/year) 30 July 1999 (30.07.99)
<b>Applicant</b> THONNARD, Joelle	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 03 February 2001 (03.02.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  Juan Cruz  Telephone No.: (41-22) 338.83.38
--	--

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number  
**WO 01/09331 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/31**,  
C07K 14/21, A61K 39/02, C07K 16/12, G01N 33/53,  
A61K 31/70, 39/40

(74) Agent: **PRIVETT, Kathryn, Louise**; SmithKline  
Beecham, Two New Horizons Court, Brentford, Middlesex  
TW8 9EP (GB).

(21) International Application Number: **PCT/EP00/07291**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: **27 July 2000 (27.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
9918041.6 **30 July 1999 (30.07.1999)** **GB**

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM BIOLOGICALS S.A.**  
[BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

**Published:**

— *Without international search report and to be republished  
upon receipt of that report.*

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **THONNARD, Joelle**  
[BE/BE]; SmithKline Beecham Biologicals s.a., Rue de  
L'Institut 89, B-1330 Rixensart (BE).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **NOVEL COMPOUNDS**

(57) Abstract: The invention provides BASB125 polypeptides and polynucleotides encoding BASB125 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

**WO 01/09331 A2**

## SEQUENCE LISTING

&lt;110&gt; SmithKline Beecham Biologicals SA

&lt;120&gt; Novel Compounds

&lt;130&gt; BM45402

&lt;160&gt; 4

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 405

&lt;212&gt; DNA

<213> *Moraxella catarrhalis*

&lt;400&gt; 1

atgatgaaaa	ttttatatgt	taccgccaca	ctaagtactg	cctttaccct	agcaagctgt	60
gcaagtaccc	ctgaaagcaa	tccaaaaaac	agttctgcta	atttaaccac	cagcttaatc	120
aaacatgcag	tcaaacaaac	ctgtcaaacc	cagctgactg	gtcatcagta	ctggaaaatt	180
gccgccatga	aattgtcttc	agaatccaaa	gccaagattt	cagaaacggc	atgcggctgt	240
gtggctgata	aagcacctga	agccgtcagc	ttgaccgagc	ttaccacagc	tgccattaat	300
ccaaatgcac	gcaactgaagt	tgcccaaaaa	attgtgcgac	actcgcttaa	accttgcatt	360
ctagagaccg	tcaatgcttt	tattgtgcca	actaccacac	gctaa		405

&lt;210&gt; 2

&lt;211&gt; 134

&lt;212&gt; PRT

<213> *Moraxella catarrhalis*

&lt;400&gt; 2

Met	Met	Lys	Ile	Leu	Tyr	Val	Thr	Ala	Thr	Leu	Met	Thr	Ala	Phe	Thr
1				5					10					15	
Leu	Ala	Ser	Cys	Ala	Ser	Thr	Pro	Glu	Ser	Asn	Pro	Lys	Asn	Ser	Ser
				20					25					30	
Ala	Asn	Leu	Thr	Thr	Ser	Leu	Ile	Lys	His	Ala	Val	Lys	Gln	Thr	Cys
				35				40					45		
Gln	Thr	Gln	Leu	Thr	Gly	His	Gln	Tyr	Trp	Lys	Ile	Ala	Ala	Met	Lys

50                                      55                                      60  
 Leu Ser Ser Glu Ser Lys Ala Lys Ile Ser Glu Thr Ala Cys Gly Cys  
 65                                      70                                      75                                      80  
 Val Ala Asp Lys Ala Pro Glu Ala Val Ser Leu Thr Glu Leu Thr Thr  
                                     85                                      90                                      95  
 Ala Ala Ile Asn Pro Asn Ala Arg Thr Glu Val Ala Gln Lys Ile Val  
                                     100                                      105                                      110  
 Arg His Ser Leu Lys Pro Cys Met Leu Glu Thr Val Asn Ala Phe Ile  
                                     115                                      120                                      125  
 Val Pro Thr Thr Thr Arg  
 130

<210> 3  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> primer

<400> 3  
 aggcagaggg aattcatgat gaaaatttta tatgttacgg 40

<210> 4  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> primer

<400> 4  
 aggcagaggg tcgacttaat ggtgatggtg atggtggcgt gtggtagtgtg gcacaataaa 60

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 00/07291

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C07K14/21 A61K39/02 C07K16/12 G01N33/53  
A61K31/70 A61K39/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! Entry/Acc.no. AI677046, 25 May 1999 (1999-05-25) WALBOT, V. ET AL.: "605048F11.x1 605 - Endosperm cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence." XP002157337 the whole document	8-10, 14, 15
A	WO 97 32980 A (LOOSMORE SHEENA M ;SCHRYVERS ANTHONY B (CA); CONNAUGHT LAB (CA); Y) 12 September 1997 (1997-09-12) the whole document	

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

15 January 2001

Date of mailing of the international search report

26/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/07291

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9732980 A	12-09-1997	US 6090576 A	18-07-2000
		AU 722681 B	10-08-2000
		AU 1865397 A	22-09-1997
		BR 9710435 A	17-08-1999
		CA 2248095 A	12-09-1997
		CN 1217748 A	26-05-1999
		EP 0885300 A	23-12-1998
		JP 2000503855 T	04-04-2000
		NZ 331777 A	29-09-1999

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

# PCT

To:

GIDDINGS, Peter John  
SMITHKLINE BEECHAM  
Corporate Intellectual Property  
Two New Horizons Court  
Brentford  
Middlesex TW8 9EP  
GRANDE BRETAGNE

12 NOV 2001  
NEW HORIZONS COURT

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year) 08.11.2001

Applicant's or agent's file reference

FB/FR/BM45402

### IMPORTANT NOTIFICATION

International application No.

PCT/EP00/07291

International filing date (day/month/year)

27/07/2000

Priority date (day/month/year)

30/07/1999

Applicant

SMITHKLINE BEECHAM BIOLOGICALS S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Büchler, S

Tel. +49 89 2399-8090





# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>FB/FR/BM45402</b>	<div style="display: flex; justify-content: space-between;"> <div> <b>FOR FURTHER ACTION</b> </div> <div>           See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)         </div> </div>	
International application No. <b>PCT/EP00/07291</b>	International filing date (day/month/year) <b>27/07/2000</b>	Priority date (day/month/year) <b>30/07/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>C12N15/31</b>		
Applicant <b>SMITHKLINE BEECHAM BIOLOGICALS S.A. et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>03/02/2001</b>	Date of completion of this report  <b>08.11.2001</b>
Name and mailing address of the international preliminary examining authority:  <div style="display: flex; align-items: center;"> <div>             European Patent Office              D-80298 Munich              Tel. +49 89 2399 - 0 Tx: 523656 epmu d              Fax: +49 89 2399 - 4465           </div> </div>	Authorized officer  <b>Grosskopf, R</b>  Telephone No. +49 89 2399 8714



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP00/07291**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-64 as originally filed

**Claims, No.:**

18-26 as originally filed

1-17 as received on 12/07/2001 with letter of 11/07/2001

**Drawings, sheets:**

1/2,2/2 as originally filed

**Sequence listing part of the description, pages:**

1,2, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/07291

listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description,      pages:
- ☐ the claims,      Nos.:
- ☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1-26
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-26
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Ad item V and VIII:**

The Applicant has isolated a nucleotide sequence from *Moraxella catarrhalis* which was arbitrarily designated "BASB125".

Although a function has not been determined, the corresponding protein seems to be immunogenic and anti-BASB125 antibodies seem to be present in human convalescent patients.

As far as the complete length proteins and polynucleotides are concerned, novelty and non-obviousness has to be acknowledged.

As far as claims are concerned which comprise a certain broadening with respect to the protein, said broadening appears to be justified since the resulting proteins have to have the essential property of the original protein, namely the same immunogenic activity (although it is not completely clear what is meant by "substantially the same immunogenic activity", even when read in the light of the description).

On the other hand, this does not apply for the broadened DNA sequences. In fact, it is well known that a deviation of only 15% in the DNA sequence (without indicating where this deviation shall take place) may result in totally unrelated proteins. This deficiency can neither be cured by a reference to the function (or even merely "substantially the same biological function") since, as mentioned above, this function is unknown.

Finally, with regard to claims which relate to medical uses of the protein, it appears to be questionable whether the experimental results shown in the present application may be considered as being sufficient in order to demonstrate or promise a successful application of said protein e.g. as a vaccine.

**CLAIMS:**

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.  
5
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.  
10
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO:2.
4. An isolated polypeptide of SEQ ID NO:2.  
15
5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:2.
- 20 6. A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein.
7. An isolated polynucleotide encoding a polypeptide as claimed in any of claims 1 to 6.
- 25 8. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide over the entire coding region.
9. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide over the entire coding region.

10. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1 and which encodes for a polypeptide that has substantially the same biological function or activity as the mature polypeptide encoded by a nucleotide sequence of SEQ ID NO:1; or a nucleotide sequence complementary to said isolated polypeptide over the entire length of SEQ ID NO:1.
11. The isolated polynucleotide as claimed in any one of claims 7 to 10 in which the identity is at least 95% to SEQ ID NO:1.
12. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2.
13. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1.
14. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.
15. An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 7 - 14.
16. A host cell comprising the expression vector of claim 15 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence of SEQ ID NO:2.
17. A process for producing a polypeptide of claims 1 to 6 comprising culturing a host cell of claim 16 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>FB/BM45402</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 00/ 07291</b>	International filing date (day/month/year) <b>27/07/2000</b>	(Earliest) Priority Date (day/month/year) <b>30/07/1999</b>
Applicant <b>SMITHKLINE BEECHAM BIOLOGICALS S.A.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 2 sheets.  
☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**MORAXELLA CATARRHALIS ANTIGEN BASB125**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT 00/07291

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C07K14/21 A61K39/02 C07K16/12 G01N33/53  
A61K31/70 A61K39/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! Entry/Acc.no. AI677046, 25 May 1999 (1999-05-25) WALBOT, V. ET AL.: "605048F11.x1 605 - Endosperm cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence." XP002157337 the whole document</p>	8-10, 14, 15
A	<p>WO 97 32980 A (LOOSMORE SHEENA M ;SCHRYVERS ANTHONY B (CA); CONNAUGHT LAB (CA); Y) 12 September 1997 (1997-09-12) the whole document</p>	

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

15 January 2001

Date of mailing of the international search report

26/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT 00/07291

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9732980 A	12-09-1997	US 6090576 A	18-07-2000
		AU 722681 B	10-08-2000
		AU 1865397 A	22-09-1997
		BR 9710435 A	17-08-1999
		CA 2248095 A	12-09-1997
		CN 1217748 A	26-05-1999
		EP 0885300 A	23-12-1998
		JP 2000503855 T	04-04-2000
		NZ 331777 A	29-09-1999
-----			